Saturday, October 31, 2026

Square Stock Rose On Thursday, Outperforms Market

ViaNews Editorial Team

December 17, 2020

Square Stock Rose On Thursday, Outperforms Market

The New York Stock Exchange ended the session with Square jumping 2% to $231.62 on Thursday while the New York Stock Exchange rose 0.68% to $14,506.70.

Square today's close was $231.62, 2.36% under its 52-week high of $237.08.

News about Square today

Times Square development draws new wave of foreign investment. According to today's article on Bloomberg Quint, "Times Square hasn't lost its cachet with foreign investors.", "Times Square in particular has taken a major hit from a pandemic that has curtailed travel, keeping the flood of tourists and office workers who typicality swamp the area at home."

Square's Sales

Square's sales growth is 387.3% for the present quarter and 112.6% for the next. The company's growth estimates for the current quarter and the next is 8.7% and 1100%, respectively.

Square's Revenue

Year-on-year quarterly revenue growth grew by 139.6%, now sitting on 7.65B for the twelve trailing months.

Square's Stock Yearly Top and Bottom Value

Square's stock is valued at $231.62 at 16:25 EST, under its 52-week high of $237.08 and way above its 52-week low of $32.33.

Square's Moving Average

Square's worth is way higher than its 50-day moving average of $193.73 and way above its 200-day moving average of $152.39.

Previous days news about Square

Axiomsl expands its global presence in Saudi Arabia with carlyle Square consUltancy. According to Business Insider on Mon Dec 14, "Our collaboration with Carlyle Square Consulting will enable financial firms to manage risk with a transparent data-driven approach, whiledelivering the clarity and insights in the calculations and the controls needed to successfully address Basel-driven requirements. ", "Prior to Carlyle Square Consultancy, Mr. Tariq Javed was a senior advisor at SAMA,where he participated in the development of national policies and reforms of the financial and banking sectors, in addition to the development and implementation of financial laws and regulations (including Basel I to Basel III) in the region."

I Squared sells grupo t-solar to cubico for $1.8 billion. According to Bloomberg Quint on Tue Dec 15, "T-Solar has 274 megawatts of installed and regulated solar power capacity in Spain and Italy, according to an emailed statement from I Squared. ", "Infrastructure investment manager I Squared Capital has agreed to sell Grupo T-Solar to Cubico Sustainable Investments Ltd. "

Marriott lays off hundreds of workers at times Square hotel. According to The Wall Street Journal on Tue Dec 15, "Marriott International Inc. is permanently laying off 850 employees from its hotel in Times Square, another sign that the hotel industry in New York City remains significantly hobbled by the coronavirus pandemic.", "The New York Marriott Marquis is located in the heart of New York City's theater district and offers views of Times Square from its eighth-floor lounge as well as several ballrooms for large events or corporate gatherings. "

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com